These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Liver function tests in patients of pulmonary tuberculosis using four different drug regimens. Akbri MZ; Fatima N; ul Haque E; Shiekh AS; Bhatti MS J Ayub Med Coll Abbottabad; 2001; 13(2):5-10. PubMed ID: 11732224 [TBL] [Abstract][Full Text] [Related]
27. Prevalence and risk factors of anti-tuberculosis drug-induced hepatitis in Malaysia. Marzuki OA; Fauzi AR; Ayoub S; Kamarul Imran M Singapore Med J; 2008 Sep; 49(9):688-93. PubMed ID: 18830542 [TBL] [Abstract][Full Text] [Related]
28. Polymorphism of PXR gene associated with the increased risk of drug-induced liver injury in Indonesian pulmonary tuberculosis patients. Zazuli Z; Barliana MI; Mulyani UA; Perwitasari DA; Ng H; Abdulah R J Clin Pharm Ther; 2015 Dec; 40(6):680-4. PubMed ID: 26417664 [TBL] [Abstract][Full Text] [Related]
29. Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Cho HJ; Koh WJ; Ryu YJ; Ki CS; Nam MH; Kim JW; Lee SY Tuberculosis (Edinb); 2007 Nov; 87(6):551-6. PubMed ID: 17950035 [TBL] [Abstract][Full Text] [Related]
30. Safety of fluoroquinolone use in patients with hepatotoxicity induced by anti-tuberculosis regimens. Ho CC; Chen YC; Hu FC; Yu CJ; Yang PC; Luh KT Clin Infect Dis; 2009 Jun; 48(11):1526-33. PubMed ID: 19400686 [TBL] [Abstract][Full Text] [Related]
32. Hepatotoxicity of anti-tuberculosis chemotherapy in patients with liver cirrhosis. Shin HJ; Lee HS; Kim YI; Lim SC; Jung JP; Ko YC; Kwon YS Int J Tuberc Lung Dis; 2014 Mar; 18(3):347-51. PubMed ID: 24670574 [TBL] [Abstract][Full Text] [Related]
33. Efficacy of stimuliv, an indigenous compound formulation, against hepatotoxicity of antitubercular drugs--a double blind study. Dange SV; Shah KU; Bulakh PM; Joshi DR Indian J Chest Dis Allied Sci; 1992; 34(4):175-83. PubMed ID: 1302750 [TBL] [Abstract][Full Text] [Related]
34. Hepatotoxicity Due to Antituberculosis Therapy among Paediatric Patients Seen at the University of Ilorin Teaching Hospital, North Central Nigeria. Aishatu G; Rasheedah I; Wahab J; Sheni M; Damilola O; Adeniyi O Ethiop J Health Sci; 2017 Mar; 27(2):115-120. PubMed ID: 28579706 [TBL] [Abstract][Full Text] [Related]
36. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Sharma SK; Balamurugan A; Saha PK; Pandey RM; Mehra NK Am J Respir Crit Care Med; 2002 Oct; 166(7):916-9. PubMed ID: 12359646 [TBL] [Abstract][Full Text] [Related]
37. Decreased activities of daily living is a strong risk factor for liver injury by anti-tuberculosis drugs. Horita N; Miyazawa N; Yoshiyama T; Tsukahara T; Takahashi R; Tsukiji J; Kato H; Kaneko T; Ishigatsubo Y Respirology; 2013 Apr; 18(3):474-9. PubMed ID: 23127245 [TBL] [Abstract][Full Text] [Related]
38. Monitoring and management of antituberculosis drug induced hepatotoxicity. Agal S; Baijal R; Pramanik S; Patel N; Gupte P; Kamani P; Amarapurkar D J Gastroenterol Hepatol; 2005 Nov; 20(11):1745-52. PubMed ID: 16246196 [TBL] [Abstract][Full Text] [Related]
39. Hepatotoxicity during treatment for multidrug-resistant tuberculosis: occurrence, management and outcome. Keshavjee S; Gelmanova IY; Shin SS; Mishustin SP; Andreev YG; Atwood S; Furin JJ; Miller A Int J Tuberc Lung Dis; 2012 May; 16(5):596-603. PubMed ID: 22410436 [TBL] [Abstract][Full Text] [Related]
40. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients]. Wada M Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]